Bobak R. Azamian - Mar 5, 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: President/CEO and Board Chair, Director
Signature: /s/ Jeffrey Farrow, Attorney-in-Fact
Stock symbol: TARS
Transactions as of: Mar 5, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/7/2025, 04:17 PM
Previous filing: Mar 19, 2024
Next filing: Mar 18, 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Stock Option (right to buy)	Award	$0	+90.7K		$0.00	90.7K	Mar 5, 2025	Common Stock	90.7K	$44.54	Direct	F1
transaction	TARS	Restricted Stock Units	Award	$0	+59.5K		$0.00	59.5K	Mar 5, 2025	Common Stock	59.5K		Direct	F2, F3

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
F2	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3	The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.